Controlled absorption diltiazem formulation
November 16, 2007. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesControlled drug releasing preparations Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating Retard form of pharmaceuticals with insoluble porous diffusion coatings Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating Pharmaceutical compositions and methods for producing alpha antagonism Pharmaceutical sustained-release compositions Aspirin tablet Drug delivery device Pharmaceutical multiple-units formulation InventorsAssigneeApplicationNo. 121224 filed on 11/16/1987US Classes:424/461, Containing polysaccharide (e.g., cellulose sugars, etc.)424/459, Organic coatings424/462, Containing solid synthetic polymers424/470, Where particles are granulated424/493, Containing polysaccharides (e.g., sugars)424/494, Cellulose derivatives424/495, Ethyl cellulose424/497Containing solid synthetic polymersExaminersPrimary: Page, Thurman K.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/12A61K 009/16 A61K 009/26 Foreign Application Priority Data1987-10-16 IEAbstractA diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid and a lubricant, and a membrane surrounding the core comprising a multiplicity of sequentially applied and dried layers, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble, naturally occurring polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of the diltiazem from the pellet at a rate allowing controlled absorption thereof over a twelve hour period following oral administration.Other References
Field of SearchParticulate form (e.g., powders, granules, beads, microcapsules, and pellets)Coated pills or tablets Containing proteins or derivatives thereof Containing polysaccharide (e.g., sugar, etc.) Containing natural gums or resins Containing solid synthetic polymers Coated (e.g., microcapsules) Containing polysaccharide (e.g., cellulose sugars, etc.) Containing polysaccharides (e.g., sugars) Cellulose derivatives Containing solid synthetic polymers Organic coatings Containing solid synthetic polymers Where particles are granulated | |
